Valuation: TScan Therapeutics, Inc.

Market Cap 98.35L 89.28L 82.47L 74.4L 1.4Cr 92Cr 1.46Cr 9.94Cr 3.93Cr 50Cr 3.69Cr 3.61Cr 156.66Cr P/E 2026 *
-0.18x
P/E 2027 * -0.21x
Enterprise Value 98.35L 89.28L 82.47L 74.4L 1.4Cr 92Cr 1.46Cr 9.94Cr 3.93Cr 50Cr 3.69Cr 3.61Cr 156.66Cr EV / Sales 2026 *
3.76x
EV / Sales 2027 * 5.9x
Free-Float
93.35%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: TScan Therapeutics, Inc.

1 day+4.07%
1 week-16.85%
Current month-13.47%
1 month-34.63%
3 months-80.61%
6 months-84.90%
Current year-84.90%
1 week 0.14
Extreme 0.1403
0.19
1 month 0.14
Extreme 0.1403
0.24
Current year 0.14
Extreme 0.1403
1.47
1 year 0.14
Extreme 0.1403
1.47
3 years 0.14
Extreme 0.1403
9.69
5 years 0.14
Extreme 0.1403
9.69
10 years 0.14
Extreme 0.1403
14.71
Manager TitleAgeSince
Chief Executive Officer 56 28/03/2023
Chief Tech/Sci/R&D Officer - 06/02/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 68 23/03/2021
Director/Board Member 56 24/05/2023
Chairman 55 12/06/2024
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Free

Chief Executive Officer

10,00,000 1.5747%
01/10/26 Free

General Counsel

3,00,000 0.4724%
20/05/26 Free

Director

67,000 0.1200%
Change 5-day change 1-year change 3-year change Capi.($)
+4.07%-16.85%-86.27%-96.82% 98.35L
+1.15%-2.81%+53.73%+71.00% 6.56TCr
-2.64%+0.07%+9.57%+89.87% 6.04TCr
-1.07%+0.55%+21.79%+87.66% 5.58TCr
+0.48%-0.98%+12.97%+118.46% 4.7TCr
-2.69%-7.62%+16.77%+25.79% 4.36TCr
-0.70%+1.43%+14.05%+45.20% 3.67TCr
-2.50%-18.72%+140.13%+665.60% 3.61TCr
-0.77%-4.34%+79.27%+59.47% 3.29TCr
-0.83%+4.96%-36.93%+398.61% 2.7TCr
Average -0.55%-3.54%+22.51%+146.48% 4TCr
Weighted average by Cap. -0.99%-1.48%+34.17%+148.26%

Financials

2026 *2027 *
Net sales 26.19L 23.78L 21.96L 19.81L 37.41L 24Cr 38.84L 2.65Cr 1.05Cr 13Cr 98.26L 96.19L 42Cr 16.67L 15.13L 13.98L 12.61L 23.8L 16Cr 24.72L 1.68Cr 66.61L 8.4Cr 62.53L 61.22L 27Cr
Net income -11Cr -10Cr -9.55Cr -8.62Cr -16Cr -1.06TCr -17Cr -115.09Cr -46Cr -574.21Cr -43Cr -42Cr -1.81TCr -8.26Cr -7.5Cr -6.93Cr -6.25Cr -12Cr -772.11Cr -12Cr -84Cr -33Cr -416.64Cr -31Cr -30Cr -1.32TCr
Net Debt - -
Projected Income Statement - Annual - TScan Therapeutics, Inc.
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company is advancing two therapeutics candidates through IND-enabling studies to treat solid tumors using in vivo-engineered TCR-T cells. In addition, the Company is seeking partnerships for its hematologic malignancies and autoimmune programs. Its construct consists of two proprietary components: dual-targeting antibodies that direct the virus to cytotoxic and helper T-cells and mediate T cell activation, and a non-targeting fusogen that mediates entry exclusively to T-cells. Its hematology program is designed to address patients who are diagnosed with hematologic malignancies and can benefit from undergoing allogeneic transplantation. Its TSC-102-A01 and TSC-102-A03 are allogeneic, donor-derived TCR-T therapy candidates targeting epitopes derived from CD45.
Employees
138
Date Price Change Volume
17/26/17 $0.1592 +9.72% 3,06,558
16/26/16 $0.1451 -9.65% 4,04,948
13/26/13 $0.1606 -4.40% 2,27,685
12/26/12 $0.1680 -9.48% 7,14,485
11/26/11 $0.1856 +0.22% 2,92,700
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - TScan Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
0.1592USD
Average target price
1.000USD
Spread / Average Target
+528.14%
  1. Stock Market
  2. Stocks
  3. TCRX Stock